A New Protein Recycling Strategy for Healthy Aging

Edited and Approved by Stephen C. Rose, PhD, MS

Could a protective process in one tissue suggest a treatment for aging elsewhere? A study in Nature Aging explores that possibility through a compound called HATC, which directs an oxygen-response protein toward cellular disposal and extended lifespan in mice. [1]

The result connects two important areas of biology: how cells respond to oxygen and how they remove proteins. Understanding that connection helps explain both the promise of the research and the questions that must be answered before anyone can judge its relevance to human longevity.

How cells sense oxygen

Cells need ways to adjust when oxygen availability changes. One involves hypoxia-inducible factor, or HIF, a protein complex that helps regulate gene activity. Its HIF-1α component is controlled partly through protein destruction. In the presence of oxygen, a chemical modification called proline hydroxylation allows a protein named VHL to recognize HIF and help mark it for removal. Foundational experiments established how this oxygen-dependent recognition works. [2]

When oxygen becomes scarce, that usual disposal route is reduced, allowing a hypoxic response to develop. The useful concept is that a cell regulates a signal not only by making a protein, but also by controlling how long the protein remains. Changes in its removal can therefore have consequences throughout the pathways it regulates. [2]

This also helps explain why targeting a regulatory protein requires care. Altering its abundance can affect several downstream processes. A useful treatment would need an appropriate degree of control in the right tissues, rather than assuming that the lowest possible protein level must be best.

A clue from the spinal disc

Intervertebral discs sit between the bones of the spine. Their hydrated central region, the nucleus pulposus, helps them absorb mechanical stress. The disc has little direct blood supply, making its cellular environment distinctive. Earlier mouse research showed that removing HIF-1α during development caused central disc cells to die and impaired the disc’s mechanical properties. These findings establish that the protein can be essential to tissue survival. [3]

The new study identified comparatively slow molecular aging in discs and linked their low-oxygen environment to HIF-1α removal through selective autophagy. Optineurin, a protein involved in selecting material for disposal, helped mediate that process. The investigators developed HATC, a HIF-1α-targeting autophagy-tethering compound, to apply a related strategy elsewhere. [1]

Molecular aging measurements and mechanical performance answer different questions. A tissue can have an interesting protective pathway while still being vulnerable to injury, degeneration, or loss of function. Discovering that pathway is valuable because it suggests something testable, not because it makes the tissue immune to aging.

What selective recycling means

Autophagy is a set of cellular processes that deliver material to lysosomes, compartments where it can be broken down. The material selected and the route used matter. In 2013, researchers showed that HIF-1α could undergo chaperone-mediated autophagy, in which helper proteins and a lysosomal receptor participate in its removal. Increasing or reducing components of that machinery changed HIF-1α levels and activity. [4]

That earlier finding should not be confused with demonstrating the precise mechanism of every newer autophagy-based intervention. Different routes can converge on lysosomal disposal while using different recognition and delivery systems. “Boosting autophagy” is therefore a much broader description than specifying which protein is being removed and how it reaches the disposal compartment. [4]

Targeted delivery has already been explored experimentally. A 2019 study identified compounds that interacted with both mutant huntingtin, the protein implicated in Huntington’s disease, and LC3, a protein associated with autophagosomes. These membrane-bound structures carry material toward lysosomal degradation. The compounds reduced mutant huntingtin and improved disease-related findings in cell, fly, and mouse models. This was a demonstration of a drug-development concept, not proof of an effective human treatment. [5]

The important design question is whether a compound can bring a chosen target into contact with the appropriate cellular machinery. A successful laboratory interaction is only a beginning. Researchers must also determine whether the compound reaches the tissues that matter, remains active long enough, and avoids removing proteins needed for normal function.

There is another distinction here: the huntingtin experiment targeted an altered, disease-causing protein. HIF-1α is a normal regulatory protein. That makes the goal closer to adjusting a biological control system than simply clearing unwanted debris. The reason for removing a protein matters as much as the ability to remove it.

What the lifespan findings show

In the new study, weekly HATC treatment began in 20-month-old mice. The survival comparison included 70 animals per group. The authors reported approximately 14% longer median lifespan and 12% longer maximum lifespan, alongside improvements in several age-related tissue abnormalities. These are preclinical findings; human longevity benefits remain unproven. [1]

Median lifespan is the point at which half the animals have died. A result at the longest-lived end of a group addresses a different part of the survival pattern. Neither percentage can be converted into additional years for a person. The numbers describe a particular experiment, with its own animals, conditions, treatment schedule, and comparison group.

Healthspan also needs careful interpretation. It refers broadly to time lived in good health, but experiments necessarily measure selected features of health. Tissue appearance, blood measurements, physical performance, and survival offer different information. Confidence grows when benefits are consistent across meaningful outcomes and independent studies, rather than resting on one favorable marker.

Why HIF biology requires balance

Earlier work illustrates the importance of location and timing. A 2022 study found excessive HIF-1α activation in the outer disc and cartilage endplate regions in experimental degeneration. Genetic interventions and an inhibitor reduced degeneration in mouse models. These findings concerned specific tissues and pathological conditions; they did not show that reducing HIF-1α is beneficial throughout the body under all circumstances. [6]

That study also connected excessive activation with increased glycolysis, the pathway that breaks down glucose, and reduced mitochondrial function. Mitochondria carry out much of a cell’s oxygen-dependent energy production. The findings show why changing an oxygen-response regulator can alter cellular metabolism, rather than merely changing one protein measurement. [6]

Read alongside the developmental study, the apparent contradiction becomes informative. A protein required for normal tissue development can also contribute to disease when its regulation changes in another setting. The therapeutic challenge is to correct a harmful pattern while preserving useful responses. That is why selectivity, treatment timing, and the extent of protein reduction deserve as much attention as a lifespan headline. [3] [6]

The broader connection with aging

Autophagy’s relationship with longevity has support beyond this particular target. In a 2018 genetic study, mice with an altered form of the autophagy protein beclin 1 had increased basal autophagy and longer lifespans in both sexes. They also showed reductions in several age-related abnormalities. The result supports investigating cellular maintenance in mammalian aging, while remaining distinct from testing a drug started later in life. [7]

The alteration weakened beclin 1’s interaction with BCL2, a protein that restrains this autophagy machinery. In practical terms, the experiment changed a control on the disposal process itself. That differs from designing a compound to help select a particular protein for removal. [7]

A genetic change present throughout an animal’s life and a medicine given after aging is established are different interventions. They can illuminate related biology without producing interchangeable evidence. The next useful experiments ask whether a proposed treatment works reproducibly, which effects depend on its intended target, and what happens with prolonged exposure.

Low oxygen itself should also be kept separate from targeted protein removal. In 2023, continuous reduced-oxygen exposure extended survival in mice with a specific DNA-repair defect and accelerated aging. The mechanism was unresolved, and the model does not establish that lowering oxygen extends ordinary human lifespan. It also cannot supply evidence that home hypoxia practices reproduce a targeted drug’s effects. [8]

What this means for readers

The most useful takeaway is a research direction: studying how cells regulate protein turnover may reveal ways to preserve function with age. Turning such a direction into medicine requires evidence about drug exposure, selectivity, long-term safety, and outcomes that matter to patients. A benefit in mice can justify further investigation without resolving those questions.

For now, this work offers no established regimen for human anti-aging use. Its value lies in making a biological idea experimentally testable. Future studies will need to show whether that idea can deliver lasting benefit while respecting the normal functions of the pathways being changed.

References

[1] Yang C, Xu Z, He ST, et al. Hypoxia-induced autophagic degradation of HIF-1α attenuates cellular aging and extends mammalian lifespan. Nat Aging. 2026;6(5):1021-1041. doi:10.1038/s43587-026-01124-z.

[2] Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. doi:10.1126/science.1059817.

[3] Merceron C, Mangiavini L, Robling A, et al. Loss of HIF-1α in the notochord results in cell death and complete disappearance of the nucleus pulposus. PLoS One. 2014;9(10):e110768. doi:10.1371/journal.pone.0110768.

[4] Hubbi ME, Hu H, Kshitiz, et al. Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J Biol Chem. 2013;288(15):10703-10714. doi:10.1074/jbc.m112.414771.

[5] Li Z, Wang C, Wang Z, et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature. 2019;575(7781):203-209. doi:10.1038/s41586-019-1722-1.

[6] Wang Z, Chen H, Tan Q, et al. Inhibition of aberrant Hif1α activation delays intervertebral disc degeneration in adult mice. Bone Res. 2022;10(1):2. doi:10.1038/s41413-021-00165-x.

[7] Fernández ÁF, Sebti S, Wei Y, et al. Disruption of the beclin 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;558(7708):136-140. doi:10.1038/s41586-018-0162-7.

[8] Rogers RS, Wang H, Durham TJ, et al. Hypoxia extends lifespan and neurological function in a mouse model of aging. PLoS Biol. 2023;21(5):e3002117. doi:10.1371/journal.pbio.3002117.